US-based BASE10 Genetics has collaborated with Korean firm DNA Link on a research project to analyse the usability of the latter’s antibody test, AccuFind COVID-19 IgG, in a healthcare setting.
Even though Covid-19 deaths and new confirmed cases continue to be on the higher side across nursing homes in the US, many infected people are recovering.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
This indicates the potential in the link between antibodies and its protective properties either generated by prior exposure to Covid-19 or by a vaccine, once available.
Currently, most antibody tests on the market need the samples sent to a laboratory for evaluation.
This not only needs extra cost but also time, constraining population-wide studies of SARS-CoV-2 antibodies.
The study intends to expand access to antibody testing outside of laboratory settings.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataBASE10 CEO Dr Michael Fang said: “An antibody test that can be done at the point of care without the need for a lab can more quickly provide information clinicians and administrators need to make decisions for their nursing home patients and staff.”
DNA Link and BASE10 plan to launch the study in December.
BASE10 Innovation vice-president Elizabeth Freund said: “DNA Link’s AccuFind performs very well in laboratory settings. The next logical step is to test its performance when used by healthcare professionals outside the lab.
“Many factors have the potential to affect test performance in lesser controlled settings so it’s an ambitious goal to be sure.
“However, if FDA believes the data demonstrates its safety and effectiveness under these conditions, we’ll be one step closer to FDA emergency use authorisation for point of care use.”
